111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a research report issued to clients and investors on Saturday, May 24th,Weiss Ratings reports.
111 Stock Performance
Shares of NASDAQ YI traded down $0.01 during mid-day trading on Friday, hitting $8.24. 16,124 shares of the stock were exchanged, compared to its average volume of 24,172. The company has a market cap of $71.23 million, a P/E ratio of -2.06 and a beta of 0.47. The stock's fifty day simple moving average is $7.90 and its two-hundred day simple moving average is $7.47. 111 has a twelve month low of $4.15 and a twelve month high of $12.90.
111 (NASDAQ:YI - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The firm had revenue of $527.14 million for the quarter.
Institutional Trading of 111
Several hedge funds have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of 111 in the first quarter valued at approximately $92,000. Deuterium Capital Management LLC acquired a new stake in shares of 111 in the first quarter valued at approximately $81,000. FIL Ltd acquired a new stake in shares of 111 in the fourth quarter valued at approximately $450,000. JPMorgan Chase & Co. increased its holdings in shares of 111 by 43,619.9% in the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after purchasing an additional 305,339 shares in the last quarter. Finally, Napean Trading & Investment Co Singapore PTE Ltd acquired a new stake in shares of 111 in the fourth quarter valued at approximately $245,000. Institutional investors and hedge funds own 21.32% of the company's stock.
111 Company Profile
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Featured Articles
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
